The JASMIN Society has been established.

September 17, 2020 / Notice

The Japanese Association of Sirolimus Medical Investigation Network (JASMIN Society) was established to support the expansion of sirolimus use for new diseases and the regulatory approval of sirolimus for new administrations and dosages, to enlighten healthcare practitioners in multiple fields about the side effects of sirolimus, and to educate young researchers engaged in basic and clinical research involving sirolimus.

Since its release, sirolimus has received approvals in about 100 countries as an inhibitor and is used as a general purpose immunosuppressive drug. Since receiving its first approval for lymphangioleiomyomatosis (Japan, 2014), sirolimus has undergone research and practical application as a treatment for over seven diseases.
In most of these cases, a path has been opened from basic research to clinical application. In fields of basic research, many new findings have resulted from the TOR Study Group.
Research into the novel action of sirolimus is a typical example of translational research, in which young researchers are expected to play an active role.

Through this website, the JASMIN Society hopes to disseminate new knowledge and promote exchanges among researchers.
The Society appreciates your cooperation and support.